Literature DB >> 14559990

Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study.

Matteo Brunelli1, John N Eble, Shaobo Zhang, Guido Martignoni, Liang Cheng.   

Abstract

It has been suggested that gains of chromosomes 7 and 17 and loss of Y occur in renal papillary adenoma and that progression to papillary renal cell carcinoma is marked by gains of additional chromosomes, most frequently 12, 16, and 20. Previous studies have included very few lesions of <5 mm in diameter, a requirement of the present definition of papillary adenoma. Ten papillary adenomas (ranging from 1 to 5 mm in diameter) from autopsy material and 10 surgically resected papillary renal cell carcinomas were studied with fluorescence in situ hybridization in paraffin sections using centromeric probes for chromosomes 7, 12, 16, 17, 20, and Y diluted 1:100 with tDenHyb1 buffer. The signals in 50 to 150 nuclei were counted in each tumor. Controls for all the probes were normal renal tissues from the same patients. Three or more signals per nucleus were frequently observed in papillary adenomas: chromosome 7 (range, 10 to 50%; > or = 30% in 9 of 10), 17 (range, 10 to 47%; > or = 30% in 7), 16 (range, 1 to 63%; > or = 10% in 5), 12 (range, 0 to 32%; > or =10% in 4), and 20 (range, 5 to 49%; > or = 10% in 5). Loss of the Y chromosome was observed in 80 to 90% of nuclei in 9 adenomas from males. Three or more signals were frequent in papillary renal cell carcinomas: chromosome 7 (range, 32 to 63%; > or =30% in 10 of 10), 17 (range, 28 to 61%; > or = 30% in 7), 16 (range, 0 to 45%; > or = 10% in 6), 12 (range, 1 to 37, > or = 10% in 5), 20 (range, 2 to 44%; > or = 10% in 4). No signal for Y was observed in 12 to 88% (> or = 81% in 6) of nuclei in 7 carcinomas from males. Statistical analysis showed no difference between adenomas and carcinomas. Gains of chromosomes 7, 17, 16, 12, and 20 and loss of the Y chromosome occur early in the evolution of papillary renal cell neoplasia in tumors that are only a few millimeters in diameter. Progressive gains of these chromosomes do not appear to correlate with the transition from adenoma to carcinoma.

Entities:  

Mesh:

Year:  2003        PMID: 14559990     DOI: 10.1097/01.MP.0000090924.90762.94

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

1.  Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour.

Authors:  Corwyn Rowsell; Neil Fleshner; Paula Marrano; Jeremy Squire; Andrew Evans
Journal:  J Clin Pathol       Date:  2007-04       Impact factor: 3.411

2.  Oncocytic papillary renal cell carcinoma: a clinicopathological study emphasizing distinct morphology, extended immunohistochemical profile and cytogenetic features.

Authors:  Qiu-Yuan Xia; Qiu Rao; Qin Shen; Shan-Shan Shi; Li Li; Biao Liu; Jin Zhang; Yan-Fen Wang; Qun-Li Shi; Jian-Dong Wang; Heng-Hui Ma; Zhen-Feng Lu; Bo Yu; Ru-Song Zhang; Xiao-Jun Zhou
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

3.  Effectiveness of intraoperative cell salvage combined with a modified leucocyte depletion filter in metastatic spine tumour surgery.

Authors:  Ya-Nan Zong; Chuan-Ya Xu; Yue-Qing Gong; Xiao-Qing Zhang; Hong Zeng; Chang Liu; Bin Zhang; Li-Xiang Xue; Xiang-Yang Guo; Feng Wei; Yi Li
Journal:  BMC Anesthesiol       Date:  2022-07-12       Impact factor: 2.376

4.  Renal oncocytoma: a comparative clinicopathologic study and fluorescent in-situ hybridization analysis of 73 cases with long-term follow-up.

Authors:  Marie Dvorakova; Rajiv Dhir; Sheldon I Bastacky; Kathleen M Cieply; Marie B Acquafondata; Carol R Sherer; Tracy L Mercuri; Anil V Parwani
Journal:  Diagn Pathol       Date:  2010-05-24       Impact factor: 2.644

5.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842

6.  Chromophobe renal cell carcinoma, oncocytic variant: a proposal of a new variant giving a critical diagnostic pitfall in diagnosing renal oncocytic tumors.

Authors:  Naoto Kuroda; Azusa Tanaka; Tadanori Yamaguchi; Kotaro Kasahara; Keishi Naruse; Yosuke Yamada; Kanako Hatanaka; Nobuo Shinohara; Yoji Nagashima; Shuji Mikami; Mototsugu Oya; Takeru Hamashima; Michal Michal; Ondrej Hes
Journal:  Med Mol Morphol       Date:  2013-01-22       Impact factor: 2.309

7.  End-stage kidney disease: gains of chromosomes 7 and 17 and loss of Y chromosome in non-neoplastic tissue.

Authors:  Ondrej Hes; Radek Síma; Jana Nemcová; Milan Hora; Stela Bulimbasic; Dmitry V Kazakov; Tomás Urge; Tomás Reischig; Miroslav Dvorák; Michal Michal
Journal:  Virchows Arch       Date:  2008-09-16       Impact factor: 4.064

Review 8.  [Cytogenetic alterations in renal tumors. Applications for comparative genomic hybridization and fluorescence in situ hybridization].

Authors:  K D Mertz; J Tchinda; R Küfer; P Möller; M A Rubin; H Moch; S Perner
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

9.  The importance of histology and cytogenetics in decision making for renal cell carcinoma.

Authors:  Julia G Garcia; Maria M Picken; Robert C Flanigan
Journal:  World J Urol       Date:  2008-04-08       Impact factor: 4.226

10.  EWSR1-PATZ1 fusion renal cell carcinoma: a recurrent gene fusion characterizing thyroid-like follicular renal cell carcinoma.

Authors:  Khaleel I Al-Obaidy; Julia A Bridge; Liang Cheng; Janos Sumegi; Victor E Reuter; Ryma Benayed; Meera Hameed; Sean R Williamson; Ondrej Hes; Fatimah I Alruwaii; Jeremy P Segal; Pankhuri Wanjari; Muhammad T Idrees; Mehdi Nassiri; John N Eble; David J Grignon
Journal:  Mod Pathol       Date:  2021-06-07       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.